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X-linked agammaglobulinemia (XLA) is one of the most frequent inherited immunodefi-
ciency diseases in man and is characterized by an almost complete arrest ofB cell differentia-
tion at the pre-B cell stage. The gene defective in XLA encodes the cytoplasmic signaling
molecule Bruton’s tyrosine kinase (Btk). Next to the CBA/N strain of mice, carrying a single
amino acid substitution mutation in the Btk gene, which results in the X-linked immunodefi-
ciency (xid) phenotype, additional mouse models have been developed to study the role of
Btk in vivo. This review discusses the analyses of Btk null-mutants, obtained by gene target-
ing in embryonic stem cells, and transgenic mice that express wild-type or mutated forms of
the Btk gene. These studies provided information on the function of Btk at several important
checkpoints throughout B cell development. Analyses of the mouse models indicated that Btk
is not essential for pre-B cell receptor signaling in the mouse. By contrast, Btk-mediated B
cell receptor signaling appears to be required for the survival of immature B cells in the bone
marrow, that have performed a successful immunoglobulin (Ig) L chain locus rearrangement,
resultirig in the expression of a non-autoreactive Ig on the membrane. Btk is also shown to be
involved in signaling pathways that govern the development of peripheral B cells, including
follicular entry, follicular maturation and plasma cell differentiation.
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X-LINKED AGAMMAGLOBULINEMIA
AND X-LINKED IMMUNODEFICIENCY
B cell development is regulated by multiple signals
derived from stromal cell contact, cytokines, antigens
and helper T cells. Biochemical analyses and in vivo
gene targeting experiments have implicated tyrosine
kinases as key regulators of many of these signaling
pathways (Satterthwaite and Witte, 1996). Bruton’s
tyrosine kinase (Btk) is one of the non-receptor protein
tyrosine kinases involved in regulating the B cell
development and function (Tsukada et al., 1993, Vetrie
et al., 1993; Rawlings et al., 1993, Thomas et al., 1993;
for review see: Sideras and Smith, 1995, Desiderio,
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1997, Conley and Cooper, 1998; Mohamed et al.
1999). Btk is a 659 amino acid protein and belongs to a
subfamily of tyrosine kinases, which also includes Itk,
Tec and Bmx. Members of this family are expressed in
haematopoietic cells and are all involved in signal
transduction pathways activated by growth or differen-
tiation factors. Btk contains, in addition to the Src
homology domains SH2 and SH3 and a single C-termi-
nal catalytic domain, a unique pleckstrin homology
(PH) domain at the N-terminus and an adjacent pro-
line- and cysteine-rich Tec homology domain. The bio-
chemistry of Btk activation after B cell receptor
signaling has recently been reviewed (Mohamed et al.,
1999).172 ALEX MAAS and RUDOLF W. HENDRIKS
Defects in the Btk protein result in the B cell differ-
entiation defects X-linked agammaglobulinemia
(XLA; Bruton’s disease) in man and X-linked immuno-
deficiency (xid) in mice. XLA patients manifest recur-
rent bacterial infections due to a profound reduction of
serum immunoglobulin (Ig) of all classes. They have
very low B cell numbers in the peripheral blood, and
those few B cells present exhibit an immature IgMhigh
phenotype (Conley 1985; Campana et al., 1990). If
stimulated with anti-CD40 in vitro these B cells are
able to proliferate and differentiate into specific Ig-pro-
ducing cells (Nonoyama et al., 1998). Plasma cells are
almost completely lacking. Because the numbers of
pre-B cells in the bone marrow are not significantly
reduced, XLA reflects impaired developmental pro-
gression or increased cell death at the transition from
pre-B to immature B cells in the bone marrow. Since
the discovery of the Btk gene, a large variety of muta-
tions, including single nucleotide substitutions, inser-
tions and deletions, distributed over the entire Btk
coding region have been characterized in 471 unrelated
XLA families (Vihinen et al., 1999). There is pheno-
typic heterogeneity among patients, even among
patients from single XLA pedigrees (Bykowsky et al.,
1996, Holsinki-Feder et al., 1998, Vihinen et al., 1999).
The arrest ofB cell development inXLA patients is not
precisely defined and was shown to vary between
patients (Campana et al., 1990). So far, it has not been
possible to correlate severity of the phenotypic presen-
tation with the genotype. Recently developed tech-
niques, such as single-cell PCR analysis, and a detailed
characterization of cell surface markers in XLA bone
marrow samples could help to investigate the role of
Btk in human B cell development. However, the large
genetic variety, differences in habitat or therapeutic
interventions between patients might complicate these
studies. Therefore, mouse models could serve as an
alternative to study the role of Btk and the effect of Btk
mutations in B cell development, since they exhibit a
uniformly genetic background and can be kept under
comparable conditions.
Since the early 1970s, an impressive amount of
data has been accumulated concerning the functional
defects in the CBA/N strain of mice, carrying the
X-linked immunodeficiency (xid) mutation (Wicker
and Scher, 1986). Shortly after the identification of
the Btk gene, it was shown that these mice have a
mutation in the Btk PH domain, of the highly con-
served Arg28 residue into cysteine (Rawlings et al.,
1993, Thomas et al., 1993). The xid phenotype in the
mouse is less severe than XLA in humans (Table I).
These mice have -50% fewer B cells in the periphery
and the residual cells exhibit an unusual IgMhigh
IgDlw phenotype. They lack the CD5
/ B-1 B cell
population and the IgM and IgG3 serum levels are
severely reduced. Btk-deficient B cells do not enter S
phase after anti-IgM stimulation in vitro. Although
the immune response of xid mice to T cell-dependent
antigens is undisturbed, they fail to make antibodies
to T cell-independent type 2 antigens in vivo.
The milder phenotype of murine xid, when com-
pared with human XLA, cannot be explained by the
nature of the mutations involved. Mutation of the
same Arg28 amino acid has been observed in patients
with classic severe XLA phenotypes (de Weers et al.,
1994a; Vihinen et al. 1999). Furthermore, the analysis
of mice deficient for Btk in their germline, which
were generated by gene targeting, showed that the
complete absence of Btk protein also results in the
mild xid phenotype (Khan et al., 1995; Hendriks et
al., 1996). The molecular basis of the differences in
phenotype between the two species is not well under-
stood, although it is shown that the severity of the xid
mutation is dependent on the genetic background of
mice (Bona et al., 1980, Khan et al., 1996). Differ-
ences can partially be caused by the relative contribu-
tions of alternative pathways of B cell differentiation
in a Btk-independent manner. An alternative explana-
tion would be that there are differences in availability
or functionality of Btk-relatives that may compensate
for the absence of functional Btk, as expression of
wild-type Btk or other Tec-family members can
restore Ca
2/ fluxes in cell lines derived from XLA
patients (Fluckinger et al., 1998). In this context, the
B cell receptor (BCR)-induced hydrolysis of phos-
pholipids in XLA cell lines was found to be severely
reduced, leading to a strong reduction in Ca
2/ flux,
whereas xid B cells demonstrate only a two-fold
reduction in phosphatidyl-inositide hydrolysis (Fluck-
inger et al., 1998, Takata & Kurosaki, 1996).ROLE OF BTK IN B CELL DEVELOPMENT 173
TABLE Comparison of the phenotypes ofhuman XLA and murine xid
’Differences between XLA and xid
1. The pre-B to immature B cell transition: almost complete arrest in XLA, and only a mild selective disadvantage for Btk-deficient
cells in xid.
2. Peripheral B lymphocyte population: absent or very low in XLA, and only a limited reduction (~50%) in xid.
3. Ig levels in the serum: very low levels of all isotypes in XLA, reduced levels of IgM and IgG3 and generally normal levels of other
isotypes in xid.
4. In vivo responses to T cell dependent antigens: low but detectable in XLA, and normal in xid.
Similarities ofXLA and xid:
1. Intrinsic B cell defect; other haematopoietic lineages are unaffected.
2. Early B cell development up to the pre-B cell stage in the bone marrow is normal.
3. Residual peripheral B cells have an immature IgMhigh surface phenotype.
4. T cell independent antibody responses in vivo are lacking.
5. Normal responses to anti-CD40 stimulation in vitro.
6. Heterozygous female carriers are normal, but have non-randomX chromosome inactivation in the mature B cell population.
7. Phenotypic heterogeneity between patients within single XLA families and between families; expression of the xid phenotype is
dependent on the background ofthe mouse strain.
a. See text for details (Conley, 1985; Wicker and Scher, 1986; Sideras and Smith 1995; Kahn et al. 1995; Hendriks et al., 1996; Nonoyama
et al., 1998).
In spite of the obvious differences in severity of the
phenotype, Btk appears to be a conserved key factor
involved in both murine and human B cell develop-
ment. Btk has been shown to be involved in the BCR
signal transduction pathways in both human (De
Weers et al., 1994b, Hinshelwood et al., 1995) and
murine (Aoki et al., 1994, Saouf et al., 1994) B cells.
The genomic organization of the murine Btk gene is
very homologous to-the human Btk gene and the Btk
proteins share 99.3% homology (Tsukada et al.,
1993). Transgenic human Btk could fully compensate
for the absence of murine Btk (Drabek et al., 1997,
Dingjan et al., 1998, Maas et al., 1997, 1999), indicat-
ing that the essential sites for Btk interaction with
other signal transduction components are conserved
between human and mouse. In addition, large scale
comparative sequence analysis of the human and
murine Btk loci revealed clusters of sequence conser-
vation in non-coding regions throughout the loci
(Oeltjen et al., 1997), which may play an essential
role in the complex gene regulation. When human Btk
was expressed under the control of the endogenous
cis-acfing elements in a 340 kb or a 240 kb transgene
construct, the expression pattern of transgenic Btk
paralleled that of the endogenous Btk (Maas et al.,
1997, A.M., unpublished results). We conclude that
also cis-acting elements that regulate Btk expression
have been conserved. Finally, in vivo competition
experiments between B cells either expressing the
wild-type Btk+ gene or a targeted disrupted Btk- allele
(see below), demonstrated that Btk- murine pre-B
cells are also hampered in their progression to the
immature B cell stage (Hendriks et al., 1996). Thus,
XLA and xid may well involve the same stages of B
cell development, but with quantitative differences
between the species (Table I).
TARGETED MUTATION OF BTK BY
INSERTION OF A LACZ REPORTER
To determine the stage in B cell development at
which defects in Btk become apparent, a mouse
model was generated in which the Btk gene was inac-
tivated through a targeted in-frame insertion of a
l-galactosidase (lacZ) reporter (Hendriks et al.,
1996). The xid phenotype in these mice confirmed the
earlier findings in Btk null-mutant mice (Khan et al.,
1995; Kerner et al., 1995) that the elimination of Btk174 ALEX MAAS and RUDOLF W. HENDRIKS
function does not lead to an almost complete block in
B cell development, which is typical for XLA in man.
The presence of the lacZ reporter enabled us to
determine the Btk expression profile in vivo. We
found that Btk is expressed throughout B cell devel-
opment, from the pro-B cell stage to the most mature
IgMlWlgDhigh peripheral B cell and activated B lym-
phoblasts stage. Btk expression is down-regulated in
plasma cells, and was also not found in T cells or NK
cells. These patterns were consistent with other Btk
expression pattern studies, either in cell lines and
leukemias (De Weers et al., 1993, Genevier et al.,
1994, Smith et al., 1994, Tsukada et al., 1993) or in
vivo using intracellular flow cytometric Btk detection
(Maas et al., 1999). Expression of the Btk gene was
not restricted to the B cell lineage. In the bone mar-
row, the ER-MP20high precursor cells of the monocyte
lineage showed high lacZ activity, whereas the
ER-MP20medium fraction of granulocyte precursors
manifested heterogeneous levels of lacZ expression
(Figure 1). In the erythroid lineage (Ter-ll9/;
ER-MP201w), lacZ activity was mainly detected in the
most immature population of large erythroid precursors
(Figure 1). This wide expression pattern of Btk sug-
gests a role for Btk in multiple signaling pathways.
Indeed, apart from its role in BCR-signaling Btk has
been implicated as a mediator of signals from the inter-
leukin 5 receptor (IL-5R), IL-6R and CD38 in B lym-
phocytes, the FceRI in myeloid cells, as well as the
collagen receptor glycoprotein VI in platelets (Sideras
and Smith, 1995, Wahl et al., 1997; Quek et al., 1998).
It was recently reported that Btk-deficient macro-
phages produce less nitric oxide than wild-type macro-
phages in response to a variety of stimuli
(Mukhopadhyay et al., 1999). Despite these findings,
Btk is only essential in B cell development and cells
from other haematopoietic lineages do not appear to be
affected inXLA nor in xid (Sideras and Smith, 1995).
Using the Btk-/lacZ mouse model it was also possi-
ble to detect selective disabilities of Btk-deficient
cells in each successive step of B cell development in
an in vivo competition strategy (Hendriks et al.,
1996). Due to the phenomenon of random x chromo-
some inactivation, B-cell precursors in Btk
+/- hetero-
zygous female mice express either the wild-type Btk+
allele or the targeted Btk/lacZ allele. The first selective
disadvantage of Btk-deficient cells became apparent at
the transition from small pre-B into immature B cells in
the bone marrow (Hendriks et al., 1996). Moreover, the
observed accumulation of Btk-cells within a small sub-
population ofCD43 pre-B cells (R.W.H., unpublished
observation) further indicated that Btk-/lacZ cells were
defective in the pre-B to B cell transition. A second
maturation arrest was found during the maturation
from IgMhighlgDlw to IgMlWlgDhigh stages in the
periphery. These findings also implied that Btk is not
involved in early signaling pathways essential for the
proliferation or differentiation of pro-B or early pre-B
cells, which is stroma cell-dependent and driven by
cytokines such as IL-7. The fraction of lacZ-expressing
cells in Btk//- heterozygote female mice did not change
during the migration of the immature B cells from the
bone marrow to the spleen, indicating that Btk expres-
sion is not relevant for this migration process (Hen-
driks et al., 1996).
CORRECTION OF THE XID PHENOTYPE BY
TRANSGENIC EXPRESSION OF BTK
We and others have generated transgenic mice in
which expression of Btk is driven by various promot-
ers, in order to correct the xid phenotype in Btk-defi-
cient mice. In these experiments, also the minimal
dosage required for Btk function was studied and the
effects of Btk overexpression on B cell development
and B cell function were analyzed.
Transgenic expression of the human Btk gene was
driven by the murine MHC class II Ea gene locus
control region (LCR), which was shown to provide
position-independent and copy-number dependent
expression from the pre-B cell stage onwards (Drabek
et al., 1997). When these transgenic mice were mated
onto a Btk-deficient background, correction of the xid
B cell defects was observed. B cell differentiated to
IgMlWlgDhigh stages in spleen or lymph nodes and
peritoneal CD5+ B-1 B cells were present. In the
serum the levels of IgM and IgG3 were in the normal
ranges, and B cell responses to the T cell independent
type II antigen di-nitrophenol-Ficoll were present. AROLE OF BTK IN B CELL DEVELOPMENT 175
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FIGURE The expression of Btk in various bone marrow populations in the mouse. Surface profile of the ER-MP20 and TER-119 markers
(top). The gated populations were analyzed for lacZ expression and the results are displayed as histograms. The Ter-119 erythroid cells were
subdivided on the basis of forward scatter (FSC) profiles into small and large cells. Solid lines represent cell populations of Btk/lacZ mice;
dashed lines represent the background lacZ activity as determined in wild-type mice
comparable rescue was also observed in heterozygous
Btk//- female mice in those B cells that were
Btk-deficient as a result of the inactivation of the X
chromosome carrying the intact endogenous Btk
gene. This apparent correction of the Btk-deficient
phenotype by expression of Btk from the pre-B cell
stage onwards indicates that Btk is not essential in the
very early stages of B cell development.176 ALEX MAAS and RUDOLF W. HENDRIKS
Using the Ig H chain enhancer and promoter to res-
cue the xid phenotype, it was shown that murine Btk
expression that equaled ~25% of endogenous levels
was sufficient to restore normal numbers of B cells in
the spleen, which were phenotypically mature (Satter-
thwaite et al., 1997). However, serum Ig levels, T cell
independent type II responses, CD5+B 1 B cell devel-
opment and in vitro responses to anti-IgM stimulation
remained significantly impaired in these animals.
These data indicated that the development of mature
conventional B cells, the development ofCD5+ B-1 B
cells, and B cell responses to antigen in vivo may
require higher levels of Btk activity.
In a next series of experiments, we increased the
expression levels of transgenic Btk by including
genomic DNA from the Btk gene (16 out of 18
introns) and the endogenous 3’ untranslated region
(Dingjan et al. 1998). Although we observed a signif-
icant overexpression (up to ~14x in the spleen of one
of the transgenic lines generated), this did not appear
to result in adverse effects on B cell development or
function. Complete correction of all xid features was
also observed by transgenic expression of the
wild-type human Btk under the control of the B-cell
specific CD19 promoter region or endogenous regula-
tory sequences present on a 340 kb yeast artificial
chromosome Btk construct (Maas et al., 1997, 1999).
Therefore it is concluded that Btk overexpression per
se does not lead to significant activation of down-
stream signaling pathways in the mouse.
EXPRESSION OF THE E41K BTKMUTANT
IN TRANSGENIC MICE
It has been shown that Btk tyrosine phosphorylation
and the in vitro kinase activity of Btk increase upon
BCR stimulation (Saouf et al., 1994; De Weers et al.,
1994; Aoki et al., 1994), placing Btk in the BCR sig-
nal transduction pathway. BCR engagement leads to
activation of phosphatidyl-inositol-triphosphate
(PIP3). PIP3 initiates Btk activation by targeting the
kinase to the plasma membrane through interactions
with the Btk PH domain, a pathway which is inhibited
by the activity of the Src homology 2 containing
inositol polyphospatase SHIP (Bolland et al., 1998;
Scharenberg et al., 1998; Pearse et al., 1999). In con-
cert with this phosphatidylinositol (PI) 3-kinase and
PIP3-dependency, Btk activity is regulated by the
(z-subunit of the Gq class of G proteins, and the Src
family kinases (Bence et al., 1997, Li et al., 1997,
Rawlings et al., 1996). Upon BCR or IL-5R stimula-
tion in B cells and FceRI in mast cells, Src family
kinases rapidly induce phosphorylation of Y551 in
the Btk kinase domain. This phosphorylation is fol-
lowed by an autophosphorylation at Y223 in the SH3
domain (Wahl et al., 1997). These concerted phospho-
rylation events were shown to be enhanced by an
E41K mutation (Glu-to-Lys) in the PH domain of Btk
(Park et al., 1996). The E41K Btk mutant, isolated
using a retroviral random mutagenisis scheme, was
able to induce transformation of NIH 3T3 fibroblast
in soft agar cultures and relieved the IL-5 dependence
of pro-B cell line Y16 (Li et al., 1995). The nature of
E41K transforming activity is associated with an
increased membrane localization (Li et al., 1995; Var-
nai, et al., 1999), thereby positioning Btk in close
proximity to other signaling molecules, needed for
activation.
To identify B cell signaling pathways activated by
Btk in vivo we generated transgenic mice, which
express an E41K human Btk mutant. When expres-
sion was driven by the CD19 promoter, B cell devel-
opment was arrested within the immature IgM+IgD
B cell stage in the bone marrow, irrespective of the
presence or absence of the endogenous intact murine
Btk gene (Maas et al., 1999). The arrest occurred at
the progression from IgMlw into IgMhigh B cells,
which reflects the first immune tolerance checkpoint
at which autoreactive B cells become susceptible to
apoptosis. Whereas the numbers of peripheral mature
B cells in spleen and lymph nodes were reduced to
< 1% of the normal numbers, a significant population
ofIgM+ plasma cells was present in the spleen. Serum
levels of IgM were substantial and increased with age
(Maas et al., 1999).
A different phenotype was observed when the
E41K mutant was expressed under the control of the
MHC class II Ea locus control region (Dingjan et al.,
1998). These mice did not exhibit any detectableROLE OF BTK IN B CELL DEVELOPMENT 177
defects in developing B cells in the bone marrow, but
manifested a deficiency of recirculating B cells. A
marked reduction of the B cell compartment was
found in the spleen. Furthermore, the mice manifested
a disorganization of the B cell areas and marginal
zones in the spleen. In the spleen, B cell areas typi-
cally contained unusually high numbers ofT cells and
the T-cell area-associated CD 1 lc+ interdigitating den-
dritic cells, which normally do not extend into B cell
follicles. These findings suggested that the expression
of the E41K mutant in peripheral B cells results in
follicular exclusion, followed by apoptosis for the
majority of peripheral B cells in the spleen. In the
lymph nodes, peripheral blood and peritoneal cavity
only very few B cells were present. Furthermore, the
expression of the E41K mutant was shown to enhance
blast formation of purified splenic B cells in vitro in
response to anti-IgM or LPS stimulation.
The differences between the two BtkE41K express-
ing mouse strains most likely reflect the earlier
expression during B cell development of the trans-
gene driven by the CD19 promoter region. The
MCHII-hBtkE41K expressing cells may well escape
negative selection i,n the bone marrow because the
expression level of the transgene had not reached a
critical threshold value. Due to the nature of the MHC
class II Ea LCR, transgenic BtkE41K expression is sig-
nificantly upregulated only after cells have arrived in
the spleen (Dingjan et al., 1998; Maas et al., 1999).
ROLE FOR BTK IN THE INDIVIDUAL STEPS
OF B CELL DEVELOPMENT
Btk is not required in pro and large pre-B cells
Several lines of evidence indicate that Btk is not criti-
cal for the assembly of the t H chain and the transi-
tion from the pro-B to the small pre-B cell stage. (1)
Pre-B cells are generally present at normal numbers
in XLA patients (Sideras and Smith, 1995). (2) In het-
erozygous Btk+/- female mice, the absence of Btk did
not result in a selective disadvantage up to the small
pre-B cell stage (Hendriks et al., 1996). (3) The xid
phenotype can be corrected by transgenic expression
of Btk from the pre-B cell stage onwards (Drabek et
al., 1997). (4) Pre-B cell receptor-mediated events,
such as allelic exclusion and proliferation of B cell
precursors that have performed a successful Ig H
chain rearrangement, proceed normally in xid orXLA
(Sideras and Smith, 1995). (5) Despite high levels of
E41K mutated Btk in the pro-B and pre-B stages, the
CD19-hBtkE41K transgenic mice showed defects only
from the immature B cell stage onwards (Maas et al.,
1999). Also when these mice were crossed on a
RAG-l-deficient background, activated Btk did not
signal developmental progression of pro-B lym-
phocytes (R.W.H., unpublished results).
Btk is critical for the transition from the pre-B
to the immature-B cell stage
The first role for Btk is evident at the transition of the
small resting pre-B cell stage to the IgMlWlgD
immature B cell stage (Figure 2). This transition is
affected both in XLA patients (Conley, 1985) and in
mice, in which B cells that lack Btk exhibited a selec-
tive disadvantage compared to B cells that express
Btk (Hendriks et al., 1996). These findings suggest
that Btk may be an essential transducer of signals that
govern Ig L chain rearrangement events, such as chro-
matin structure changes that allow the recombinase
access to the Ig L chain gene segments. Alternatively,
Btk-mediated signals may regulate the re-expression
of the RAG gene products, which are absent in the
large cycling pre-B cells and reactivated in small rest-
ing pre-B cells for Ig L chain rearrangement
(Grawunder et al., 1995). Finally, Btk signaling may
regulate the survival of immature B cells that have
performed a successful Ig L chain rearrangement.
This would be supported by the finding that Bcl-2
expression is reduced and surface Ig mediated Bcl-xL
induction is absent in xid B cells (Anderson et al.,
1996; Woodland et al., 1996; Solvason et al., 1998).178 ALEX MAAS and RUDOLF W. HENDRIKS
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FIGURE 2 Role of Btk in murine B cell development. The model ofB cell development is based on the nomenclature according to Hardy et
al., 1995. The stages at which there is evidence for a role of Btk are indicated
A role for Btk in central immune tolerance
With the expression of a complete IgM molecule and
the resultant antigen specificity on the cell surface,
immature B cells become susceptible to immune tol-
erance (Goodnow, 1996). Recently, two subpopula-
tions within the immature B cell stage with
differences in apoptosis sensitivity were described
(Melamed et al., 1998). Upon BCR stimulation in
vitro, IgMlWlgD immature B cells performed sec-
ondary L chain rearrangements, a process termed
receptor editing. Under these conditions, the slightly
more mature IgMhighlgD B cells were susceptible to
apoptosis. The expression of the activated BtkE41K
mutant driven by the CD19 promoter resulted in an
almost complete absence of IgMhighlgD- immature B
cells, while IgMlWlgD cells were still present (Maas
et al., 1999). Although the possibility that constitutive
activation of Btk by the E41K mutation leads to a
general defect that impedes the survival or affects
their developmental capacities cannot be excluded, it
is attractive to hypothesize that expression of BtkE41K
mimics B cell receptor engagement. The findings in
the CD19-hBtkE41K mouse would then imply that Btk
is involved in the BCR signal pathway that eliminates
auto-reactive B cells at the IgMhighlgD- B cell stage
in the bone marrow.
Btk-mediated signals guide follicular entry,
maturation and survival
Mice in which E41K Btk expression is driven by the
MHC class II LCR display normal B cell develop-
ment in the bone marrow, but manifest a deficiency of
recirculating follicular B cells (Dingjan et al., 1998).
The B cells that were present in the spleen had an
IgMhighHSAtighB220lw surface phenotype, resem-
bling immature cells that have recently left the bone
marrow. In this respect, these cells paralleled B cells
that are autoreactive for antigens present in the
periphery, which are excluded from follicles and
eliminated (Russel et al., 1991, Eibel et al., 1994,
Goodnow et al., 1995). It is likely that the activated
state of the MHCII-hBtkE41K B cells may result in an
inhibition of follicular entry. As T helper cell-derived
rescue signals are absent, follicular exclusion will
result in apoptosis of most of the B cells. In summary,
the findings in the MHCII-hBtk
E4]K mice imply that
Btk-mediated BCR signals are decisive for the choice
between follicular entry and follicular exclusion. This
would be consistent with the block ofB cell follicular
entry in mice with targeted mutations in other BCR
signaling components, such as Ig-ot or Syk, (Torres et
al., 1996, Turner et al., 1995).ROLE OF BTK IN B CELL DEVELOPMENT 179
After follicular entry, B cells are positively selected
to become long-lived IgMlWIgDhigh recirculating B
cells, a process which is probably mediated by
low-level BCR signaling (Gu et al., 1991, Lam et al.,
1997). Btk-deficient B cells are not excluded from B
cell follicles, but fail to develop from the immature
IgMhighIgDlw stage into the long-lived recirculating
follicular IgMlWIgDhigt B cell stage (Wicker and
Scher, 1986, Khan et al., 1995, Hendriks et al., 1996).
As xid B cells were shown to express only low levels
of the anti-apoptotic bcl-2 protein and to undergo
spontaneous apoptosis more rapidly than wild-type B
cells in vitro (Woodland et al., 1996), we conclude
that Btk must play a critical role in survival and matu-
ration into long-lived recirculating B cells.
Btk and plasma cell differentiation
Another role for Btk was apparent from in the
CD19-hBtkE41K transgenic mice. As the block at the
IgMhighIgD immature B cell stage was leaky, B cells
were found in the peripheral organs in very low num-
bers, almost exclusively beating an
IgMhighHSAhighB22(Jlw immature phenotype.
Despite the very severe reduction of the mature B cell
pool, significant numbers of IgM secreting plasma
cells were present in the splenic red pulp. Therefore,
we conclude that Btk activation quite efficiently
induced terminal differentiation of the residual B cells
into IgM-producing plasma cells, apparently without
functional selection. In the CD19-hBtkE41K trans-
genic mice, serum levels of the IgG and IgA sub-
classes were severely decreased, confirming that
constitutive BCR signaling in the absence of co-stim-
ulation by CD40-CD40L interactions did not induce
B cells to perform IgH chain class switch or germinal
center formation (Foy et al., 1996).
CONCLUDING REMARKS
The analyses of the various mouse models generated
show that Btk is expressed throughout B cell develop-
ment and that signaling cascades activated by Btk are
critical at several checkpoints throughout B cell dif-
ferentiation. In all maturation steps the strength of the
BCR-mediated signal is critical to guide further
development. In the absence of Btk and even more
so in the case of constitutive activation, B cell
development is impaired. The molecular mechanisms,
by which Btk mediates B cell development, cell acti-
vation and cell death need to be further elucidated,
and await a detailed characterization of downstream
signaling targets and pathways. Very likely, the pro-
teins that interact with the different domains of Btk
vary between the individual stages of B cell develop-
ment. The biochemical characterization of down-
stream signaling targets at these individual stages
could be facilitated by the generation of transgenic
mice that express tagged forms of the Btk protein.
Similar approaches could be used for other compo-
nents of the BCR signaling pathways and would
eventually lead to a better insight in B cell develop-
ment and function.
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